Analyst Ratings For PCRX – Pacira Pharmaceuticals (NASDAQ:PCRX)
Today, BMO Capital Markets raised its price target on PCRX – Pacira Pharmaceuticals (NASDAQ:PCRX) to $34.00 per share.
Some recent analyst ratings include
- 4/9/2018-JPMorgan Chase Reiterated Rating of Hold.
- On 1/10/2018 David M. Stack, CEO, sold 28,885 with an average share price of $40.19 per share and the total transaction amounting to $1,160,888.15.
- On 12/15/2017 Lauren Bullaro Riker, VP, sold 340 with an average share price of $43.70 per share and the total transaction amounting to $14,858.00.
- On 11/20/2017 James B. Jones, SVP, sold 850 with an average share price of $41.11 per share and the total transaction amounting to $34,943.50.
- On 11/17/2017 Kristen Marie Williams, CAO, sold 10,000 with an average share price of $40.00 per share and the total transaction amounting to $400,000.00.
- On 11/15/2017 David M Stack, CEO, sold 58,885 with an average share price of $38.34 per share and the total transaction amounting to $2,257,650.90.
- On 11/10/2017 Mark A Kronenfeld, Director, bought 1,000 with an average share price of $41.60 per share and the total transaction amounting to $41,600.00.
- On 8/22/2017 Paul J Hastings, Director, sold 1,044 with an average share price of $36.15 per share and the total transaction amounting to $37,740.60.
Recent Trading Activity for PCRX – Pacira Pharmaceuticals (NASDAQ:PCRX)
Shares of PCRX – Pacira Pharmaceuticals closed the previous trading session at 34.18 up +0.88 2.64% with 33.625 shares trading hands.